| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Peter M Elias | |
| Joan S Wakefield | |||
| P2860 | cites work | Gene-environment interaction in the onset of eczema in infancy: filaggrin loss-of-function mutations enhanced by neonatal cat exposure | Q21090137 |
| A proteolytic cascade of kallikreins in the stratum corneum | Q24338337 | ||
| The role of microorganisms in atopic dermatitis | Q24683941 | ||
| The spectrum of pathogenic mutations in SPINK5 in 19 families with Netherton syndrome: implications for mutation detection and first case of prenatal diagnosis | Q28213469 | ||
| Gene polymorphism in Netherton and common atopic disease | Q28215592 | ||
| The skin barrier as an innate immune element | Q28235928 | ||
| Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7 | Q28261469 | ||
| Histidine-rich proteins (filaggrins): Structural and functional heterogeneity during epidermal differentiation | Q28262725 | ||
| Genetic association between an AACC insertion in the 3'UTR of the stratum corneum chymotryptic enzyme gene and atopic dermatitis | Q28266519 | ||
| IL-31: a new link between T cells and pruritus in atopic skin inflammation | Q28295839 | ||
| Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome | Q28306299 | ||
| The proteins elafin, filaggrin, keratin intermediate filaments, loricrin, and small proline-rich proteins 1 and 2 are isodipeptide cross-linked components of the human epidermal cornified cell envelope | Q28910329 | ||
| Murine atopic dermatitis responds to peroxisome proliferator-activated receptors alpha and beta/delta (but not gamma) and liver X receptor activators | Q30494234 | ||
| Filaggrin deficiency confers a paracellular barrier abnormality that reduces inflammatory thresholds to irritants and haptens | Q30494794 | ||
| Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data | Q31968983 | ||
| Serum IgE autoantibodies target keratinocytes in patients with atopic dermatitis | Q33334815 | ||
| Objective assessment of the skin of children affected by atopic dermatitis: a study of pH, capacitance and TEWL in eczematous and clinically uninvolved skin | Q71125893 | ||
| IL-1 beta activation in human epidermis | Q71403582 | ||
| In vivo studies concerning a pH gradient in human stratum corneum and upper epidermis | Q72399892 | ||
| The characterization of human epidermal filaggrin. A histidine-rich, keratin filament-aggregating protein | Q72691636 | ||
| Evidence for the existence of a self-regulated enzymatic process within the human stratum corneum -an unexpected role for urocanic acid | Q74199240 | ||
| Does the tail wag the dog? Role of the barrier in the pathogenesis of inflammatory dermatoses and therapeutic implications | Q74329254 | ||
| Absence of the granular layer and keratohyalin define a morphologically distinct subset of individuals with ichthyosis vulgaris | Q74641815 | ||
| Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis | Q79345424 | ||
| The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study | Q79453247 | ||
| Glucocorticoid blockade reverses psychological stress-induced abnormalities in epidermal structure and function | Q79954892 | ||
| Filaggrin expression in oral, nasal, and esophageal mucosa | Q80439121 | ||
| Analysis of SPINK 5, KLK 7 and FLG genotypes in a French atopic dermatitis cohort | Q81568617 | ||
| Interleukin-4 suppresses the enhancement of ceramide synthesis and cutaneous permeability barrier functions induced by tumor necrosis factor-alpha and interferon-gamma in human epidermis | Q81626174 | ||
| Calcineurin inhibitors for the treatment of atopic dermatitis | Q82593357 | ||
| Skin barrier function and allergic risk | Q82996787 | ||
| Epidermal pathogenesis of inflammatory dermatoses | Q33709614 | ||
| Hypothesis: from epidermal barrier dysfunction to atopic disorders | Q33748707 | ||
| Abnormal skin barrier in the etiopathogenesis of atopic dermatitis | Q33779047 | ||
| A homozygous frameshift mutation in the mouse Flg gene facilitates enhanced percutaneous allergen priming. | Q33858072 | ||
| Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. Evidence for a new group of allergens | Q33902195 | ||
| Psychological stress perturbs epidermal permeability barrier homeostasis: implications for the pathogenesis of stress-associated skin disorders | Q33933323 | ||
| Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitis | Q34089457 | ||
| Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children | Q34136595 | ||
| The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. | Q34517119 | ||
| Pathophysiologic basis for growth failure in children with ichthyosis: an evaluation of cutaneous ultrastructure, epidermal permeability barrier function, and energy expenditure | Q34549121 | ||
| Loss-of-function mutations in the filaggrin gene and allergic contact sensitization to nickel | Q34655451 | ||
| Stratum corneum defensive functions: an integrated view | Q36228049 | ||
| Acute modulations in permeability barrier function regulate epidermal cornification: role of caspase-14 and the protease-activated receptor type 2 | Q36357354 | ||
| New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions. | Q36525095 | ||
| Skin barrier function, epidermal proliferation and differentiation in eczema | Q36556120 | ||
| The development of allergic inflammation | Q36613696 | ||
| Black box warning for topical calcineurin inhibitors and the death of common sense. | Q36644148 | ||
| Epidermal keratinocytes as the forefront of the sensory system | Q36730785 | ||
| Filaggrin's fuller figure: a glimpse into the genetic architecture of atopic dermatitis. | Q36821959 | ||
| An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance. | Q37049990 | ||
| Potential new indications of topical calcineurin inhibitors. | Q37049993 | ||
| Superantigen profile of Staphylococcus aureus isolates from patients with steroid-resistant atopic dermatitis | Q37087527 | ||
| Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms | Q37105441 | ||
| "Outside-to-inside" (and now back to "outside") pathogenic mechanisms in atopic dermatitis. | Q37137538 | ||
| Cytokine modulation of atopic dermatitis filaggrin skin expression | Q37159649 | ||
| Co-regulation and interdependence of the mammalian epidermal permeability and antimicrobial barriers | Q37164058 | ||
| Maintenance of an acidic stratum corneum prevents emergence of murine atopic dermatitis | Q37226147 | ||
| Filaggrin in atopic dermatitis. | Q37261751 | ||
| Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome | Q37273142 | ||
| Emerging drugs for atopic dermatitis | Q37392901 | ||
| Role of topical calcineurin inhibitors in the treatment of seborrheic dermatitis: a review of pathophysiology, safety, and efficacy | Q37394778 | ||
| LEKTI-1 in sickness and in health | Q37494706 | ||
| Epidermal barrier dysfunction in atopic dermatitis. | Q37507508 | ||
| Endogenous antimicrobial peptides and skin infections in atopic dermatitis | Q40698186 | ||
| Studies on skin surface barrier functions:--skin surface lipids and transepidermal water loss in atopic skin during childhood | Q40956797 | ||
| Stratum corneum architecture, metabolic activity and interactivity with subjacent cell layers | Q41186834 | ||
| Transepidermal water loss in dry and clinically normal skin in patients with atopic dermatitis | Q42155891 | ||
| Topical calcineurin inhibitors compromise stratum corneum integrity, epidermal permeability and antimicrobial barrier function | Q42458936 | ||
| Serine protease signaling of epidermal permeability barrier homeostasis | Q42495244 | ||
| Deficiency of PPARbeta/delta in the epidermis results in defective cutaneous permeability barrier homeostasis and increased inflammation | Q42517793 | ||
| Profilaggrin, a high-molecular-weight precursor of filaggrin in human epidermis and cultured keratinocytes | Q42813725 | ||
| A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients | Q43516423 | ||
| Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. | Q43639646 | ||
| Staphylococcus aureus enterotoxins induce histamine and leukotriene release in patients with atopic eczema | Q43725483 | ||
| Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity | Q44078720 | ||
| Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities | Q44326567 | ||
| pH directly regulates epidermal permeability barrier homeostasis, and stratum corneum integrity/cohesion | Q44525316 | ||
| Unexpected high serum levels of tacrolimus after a single topical application in an infant | Q44582742 | ||
| Increased stratum corneum serine protease activity in acute eczematous atopic skin | Q44849109 | ||
| Does topical tacrolimus induce lentigines in children with atopic dermatitis? A report of three cases. | Q45228837 | ||
| Molluscum contagiosum infection associated with pimecrolimus use in pityriasis alba | Q45237217 | ||
| Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. | Q45251615 | ||
| Antimicrobial activity of sphingosines | Q46078288 | ||
| Stratum corneum acidification is impaired in moderately aged human and murine skin | Q46091470 | ||
| In vitro and in vivo antistaphylococcal activity of human stratum corneum lipids | Q46091704 | ||
| In human epidermis, beta-defensin 2 is packaged in lamellar bodies | Q46140214 | ||
| The objective severity assessment of atopic dermatitis score: an objective measure using permeability barrier function and stratum corneum hydration with computer-assisted estimates for extent of disease | Q46161011 | ||
| Keratinocytes store the antimicrobial peptide cathelicidin in lamellar bodies. | Q46187560 | ||
| Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use. | Q46241396 | ||
| Analysis of the individual and aggregate genetic contributions of previously identified serine peptidase inhibitor Kazal type 5 (SPINK5), kallikrein-related peptidase 7 (KLK7), and filaggrin (FLG) polymorphisms to eczema risk | Q46386883 | ||
| Sustained serine proteases activity by prolonged increase in pH leads to degradation of lipid processing enzymes and profound alterations of barrier function and stratum corneum integrity | Q46509940 | ||
| Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled study | Q46685590 | ||
| Eczema herpeticum during treatment of atopic dermatitis with 1% pimecrolimus cream | Q46882276 | ||
| IL-4 suppresses the recovery of cutaneous permeability barrier functions in vivo | Q46932366 | ||
| Staphylococcus aureus clonal dynamics and virulence factors in children with atopic dermatitis | Q47238582 | ||
| Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes | Q47640250 | ||
| Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse | Q48617837 | ||
| Ceramide and cholesterol composition of the skin of patients with atopic dermatitis. | Q50903373 | ||
| Comparison of epidermal hydration and skin surface lipids in healthy individuals and in patients with atopic dermatitis. | Q52549794 | ||
| Mite and cockroach allergens activate protease-activated receptor 2 and delay epidermal permeability barrier recovery. | Q52585412 | ||
| Histidine-rich protein of the keratohyalin granules. Source of the free amino acids, urocanic acid and pyrrolidone carboxylic acid in the stratum corneum. | Q53931495 | ||
| Topical calcineurin inhibitors labeling: putting the "box" in perspective. | Q55042459 | ||
| Filaggrin breakdown to water binding compounds during development of the rat stratum corneum is controlled by the water activity of the environment. | Q55060784 | ||
| Stratum corneum moisturization at the molecular level. | Q55065720 | ||
| Atopic Dermatitis | Q56688397 | ||
| Breaking the (Un)Sound Barrier: Filaggrin Is a Major Gene for Atopic Dermatitis | Q58859847 | ||
| The barrier function in atopic dry skin. Disturbance of membrane-coating granule exocytosis and formation of epidermal lipids? | Q67978921 | ||
| Decreased level of ceramides in stratum corneum of atopic dermatitis: an etiologic factor in atopic dry skin? | Q70124237 | ||
| Filaggrin linker segment peptide and cystatin alpha are parts of a complex of the cornified envelope of epidermis | Q71053835 | ||
| P433 | issue | 3 | |
| P921 | main subject | atopic dermatitis | Q268667 |
| pathogenesis | Q372016 | ||
| P304 | page(s) | 282-295 | |
| P577 | publication date | 2011-12-01 | |
| P1433 | published in | Clinical Reviews in Allergy & Immunology | Q1932354 |
| P1476 | title | Therapeutic implications of a barrier-based pathogenesis of atopic dermatitis | |
| P478 | volume | 41 |
| Q34353182 | Abnormal epidermal barrier recovery in uninvolved skin supports the notion of an epidermal pathogenesis of psoriasis |
| Q47243988 | Anti-Inflammatory and Skin Barrier Repair Effects of Topical Application of Some Plant Oils |
| Q47167286 | Association between Stress and the HPA Axis in the Atopic Dermatitis |
| Q37827743 | Atopic dermatitis: new trends and perspectives |
| Q38375544 | Comparison of the Simple Patient-Centric Atopic Dermatitis Scoring System PEST with SCORAD in Young Children Using a Ceramide Dominant Therapeutic Moisturizer. |
| Q41823296 | Current Understanding in Pathogenesis of Atopic Dermatitis |
| Q28085608 | Defects of corneocyte structural proteins and epidermal barrier in atopic dermatitis |
| Q24186075 | Emollients and moisturisers for eczema |
| Q38976344 | Emollients and moisturisers for eczema. |
| Q36066892 | Evaluation of the effect of a 0.0584% hydrocortisone aceponate spray on clinical signs and skin barrier function in dogs with atopic dermatitis |
| Q90271409 | Exosomes from Human Adipose Tissue-Derived Mesenchymal Stem Cells Promote Epidermal Barrier Repair by Inducing de Novo Synthesis of Ceramides in Atopic Dermatitis |
| Q37092236 | Filaggrin-dependent secretion of sphingomyelinase protects against staphylococcal α-toxin-induced keratinocyte death |
| Q48247956 | IL-1β induces thymic stromal lymphopoietin and an atopic dermatitis-like phenotype in reconstructed healthy human epidermis |
| Q38152889 | Lipid abnormalities and lipid-based repair strategies in atopic dermatitis |
| Q34658901 | Local rhamnosoft, ceramides and L-isoleucine in atopic eczema: a randomized, placebo controlled trial |
| Q35305118 | Loss of sirtuin 1 (SIRT1) disrupts skin barrier integrity and sensitizes mice to epicutaneous allergen challenge. |
| Q26827984 | Mechanisms of abnormal lamellar body secretion and the dysfunctional skin barrier in patients with atopic dermatitis |
| Q38174084 | New approaches to the prevention of childhood atopic dermatitis |
| Q36244943 | On the role of skin in the regulation of local and systemic steroidogenic activities. |
| Q36449701 | Prevention of atopic dermatitis. |
| Q34200863 | Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response |
| Q102210960 | Role of 11β-hydroxysteroid dehydrogenase type 1 in the development of atopic dermatitis |
| Q36447481 | Role of the steroidogenic acute regulatory protein in health and disease |
| Q38193353 | Skin barrier function in infancy: a systematic review |
| Q93016326 | Staphylococcus aureus and the Cutaneous Microbiota Biofilms in the Pathogenesis of Atopic Dermatitis |
| Q33916807 | Th2 cytokines increase Staphylococcus aureus alpha toxin-induced keratinocyte death through the signal transducer and activator of transcription 6 (STAT6) |
| Q47572447 | The practical understanding and treatment of asthma |
| Q36494773 | Topical antihistamines display potent anti-inflammatory activity linked in part to enhanced permeability barrier function |
| Q93077958 | Treatment with Docosahexaenoic Acid Improves Epidermal Keratinocyte Differentiation and Ameliorates Inflammation in Human Keratinocytes and Reconstructed Human Epidermis Models |
| Q87098251 | [Basics of topical therapy] |
Search more.